1. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
2. Agency for Health Care Policy and Research. Management of cancer pain: clinical practice guidelines AHCPR publication 94-0592. Rockville, MD: US Department of Health and Human Services; 1994.
3. Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397–402.
4. Bell R, Tripathy D, Body JJ et al. Oral ibandronate: an effective, convenient and well-tolerated therapy for metastatic bone disease. Support Care Cancer 2003; 11: 415 (Abstract A-105).
5. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–93.
6. Body JJ. Bisphosphonates for metastatic bone pain. Support Care Cancer 1999; 7: 1–3.
7. Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998; 16: 3890–9.
8. Body JJ, Kanis J, Diel I, Bergstrom B. Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc ASCO 2003; 22: 46 (Abstract 184).
9. Body JJ, Diel IJ, Lichinitser MR et al. the MF 4265 study group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–405.
10. Body JJ, Diel IJ, Lichinitser M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–7.
11. Bonica JJ. Management of cancer pain. Acta Anaesthesiol Scand 1982; 74: 75–82.
12. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676–9.
13. Coleman RE. Assessment of response to treatment. In: RD.Rubens, I.Forgelman (eds.). Bone metastases: diagnosis and treatment. Berlin: Springer; 1991; p. 99–120.
14. Coleman RE, Woll PJ, Miles M et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropyli-dene)-1,1-bisphosphonate (APD). Br J Cancer 1988; 58: 621–5.
15. Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with i.v. pamidronate: results from a multinational randomised controlled trial. J Clin Oncol 1996; 14: 2552–9.
16. Costanino J. The impact of hormonal treatments on quality of life in patients with metastatic breast cancer. Clin Ther 2002; 24: C26–C42.
17. Diel IJ, Body JJ, Tripathy D, Bergstrom B. Oral daily ibandronate in women with metastatic breast cancer: a pooled safety analysis. Proc ASCO 2003; 22: 47 (Abstract 186).
18. Elomaa I, Kylmala T, Tammela T et al. Effect of oral clodronate on bone pain—a controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992; 24: 159–66.
19. Ernst DS, MacDonald RN, Paterson AH et al. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992; 7: 4–11.
20. Ernst DS, Brasher P, Hagen N et al. Controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. Proc Am Soc Clin Oncol 1994; 1:431 (Abstract 1478).
21. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bispho-sphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78: 157–69.
22. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–91.
23. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 203844.
24. Jagdev SP, Purohit OP, Heatley S et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001; 12: 1433–8.
25. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001; 28: 28–34.
26. Kristensen B, Ejlertsen B, Groenvold M et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246: 67–74.
27. Lahtinen R, Lansko M, Palva I et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–52.
28. Lippman ME, Lichter AS, Danford DN. Diagnosis and management of breast cancer. Philadelphia, PA: WB Saunders; 1998; p. 569–74.
29. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082–90.
30. Mancini I, Duman JC, Toth C, Body JJ. Short-term treatment with the bisphosphonate ibandronate for opioid resistant metastatic bone pain. Bone 2002; 30 (Suppl. 3): 51 (Abstract B56).
31. Marsoni S, Hurson S, Eisenberger M. Chemotherapy of bone metastases. In: S.Garranttini (ed.). Bone resorption, metastases and dipho-sphonates. New York, NY: Raven Press; 1985; p. 181–95.
32. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1–18.
33. Ohlmann C, Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 2003; 11: 396 (Abstract A-38).
34. O'Rourke N, McCloskey E, Houghton F et al. Double-blind, placebo-controlled, dose-response trial or oral clodronate in patients with bone metastases. J Clin Oncol 1995; 13: 929–34.
35. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002; 1: CD003474.
36. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377–87.
37. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68.
38. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42: 895–906.
39. Small EJ, Smith MR, Seaman JJ et al. Combined analysis of two multicenter randomizd, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastastic prostate cancer. J Clin Oncol 2003; 21: 4277–84.
40. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, double-blind, placebo-controlled study. J Urol 1989; 141: 85–7.
41. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26: 151–68.
42. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17: 846–54.
43. Tripathy D, Pecherstorfer M, Bartl R et al. Reduction in risk of skeletal events with ibandronate in the treatment of metastatic breast cancer. Support Care Cancer 2003; 11: 427 (Abstract A-152).
44. World Health Organization. Cancer pain relief and palliative care: report of a WHO expert committee. Geneva, Switzerland: World Health Organization; 1990.

Л.Г.Бабичева

Кафедра онкологии ГОУ ДПО РМАПО, Москва